Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Trisenox arsenic trioxide: Phase III data

An open-label, European Phase III trial in 156 patients with newly diagnosed low- to intermediate-risk APL showed that Trisenox plus all-trans retinoic acid (ATRA) met the

Read the full 260 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE